Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on April 3, 2025
HealWell Solutions and Lovell Announce Partnership to Increase Access to Antimicrobial Gel for VA, DoD
EIN Presswire
·
April 3, 2025
Partnership between HealWell Solutions and Lovell Enhances Access to Antimicrobial Gel for Veterans and Military Health Systems PENSACOLA, FL, UNITED STATES, April 3, 2025 /EINPresswire.com/ -- Lovell® Government Services and HealWell HealthCare …
Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs
GlobeNewswire
·
April 3, 2025
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government’s …
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
GlobeNewswire
·
April 3, 2025
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points Educational Symposium Focuses on Advancing GBS Care and …
Anne Whitaker Appointed as Non-Executive Director
GlobeNewswire
·
April 3, 2025
MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United …
Praxis Precision Medicines to Participate in Upcoming April Conferences
GlobeNewswire
·
April 3, 2025
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized …
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
GlobeNewswire
·
April 3, 2025
MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and provide a …
Theratechnologies annoncera ses résultats financiers du premier trimestre de l’exercice financier de 2025 et fera une mise à jour de ses activités
GlobeNewswire
·
April 3, 2025
MONTRÉAL, 03 avr. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, annonce aujourd’hui que la Société dévoilera ses résultats financiers …
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 3, 2025
-- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 -- -- Signed Multiple Development Agreements with New and Existing Customers -- -- Strengthened Balance Sheet through Sale of Excess Capital Equipment, Raising Approximately $17.0 Million -- …
Vaxil: Management and Operational Update
GlobeNewswire
·
April 3, 2025
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to make the following updates regarding the Company’s activities, …
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
GlobeNewswire
·
April 3, 2025
EDEN PRAIRIE, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological …
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
GlobeNewswire
·
April 3, 2025
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination therapy New interim data for the vebreltinib development …
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity
GlobeNewswire
·
April 3, 2025
VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based …
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 3, 2025
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on April 1, 2025, it awarded …
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
April 3, 2025
Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025 Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; …
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 3, 2025
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized …
Jointechlabs Names Dr. George A. Skarpas Scientific Clinical Lead for EU Clinical Studies
EIN Presswire
·
April 3, 2025
Renowned orthopedic surgeon and expert brings clinical trial expertise, strengthening Jointechlabs' collaboration with the ESSKA-ORBIT Consensus Group. BRANDON, FL, UNITED STATES, April 3, 2025 /EINPresswire.com/ -- Jointechlabs, Inc., a Florida-based …
Best SARMs For Cutting, Bulking & Muscle Growth 2025: Top Fat Loss Sarms Stack For Sale On The Market - CrazyBulk
GlobeNewswire
·
April 3, 2025
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Welcome to the world of SARMs, the selective androgen receptor modulators that have gained popularity in the fitness and bodybuilding community. SARMs offer a unique approach to enhancing muscle growth, …
HealthRecon Connect Achieves ISO 22301:2019 Certification for Business Continuity Management
GlobeNewswire
·
April 3, 2025
DALLAS, April 03, 2025 (GLOBE NEWSWIRE) -- HealthRecon Connect is proud to announce that it has been awarded the ISO 22301:2019 certification, an internationally recognized standard for Business Continuity Management Systems (BCMS). This achievement …
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
GlobeNewswire
·
April 3, 2025
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new CIS-Demasking1 cytokine bispecific technology. CLEC-1, a novel immune checkpoint target. NANTES, France – April 3, 2025, 6:00 p.m. CET - …
OSE Immunotherapeutics présente ses dernières avancées précliniques en Immuno-Oncologie - Au congrès annuel 2025 de l’AACR
GlobeNewswire
·
April 3, 2025
OSE Immunotherapeutics présente ses dernières avancées précliniques en Immuno-Oncologie Au congrès annuel 2025 de l’AACR OSE-CYTOMASK®, une nouvelle technologie bispécifique de CIS-Démasquage1 des cytokines. CLEC-1, une cible innovante de point de contrôle …